fda warning compounded peptides bpc-157 tb-500 2024 2025 panel votes to place popular peptide on compounding list Regulatory Alert: The Legal Status

Use of GLP-1 medications, such as Trulicity, Ozempic, Mounjaro or Victoza, to treat type-2 diabetes still will be covered provided that the treatment is medically necessary and prior authorization is obtained

Stable gastric pentadecapeptide BPC 157 as a therapy for the disturbances of the venous system

Shaking can destroy the peptide bonds

Unlike corticosteroid injections (which reduce pain short-term but damage cartilage long-term), BPC-157 appears to be cartilage-sparing and potentially cartilage-supportive making it relevant for early-stage osteoarthritis or post-injury joint degradation

A revved up metabolism can cause temporary exhaustion